Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan versus standard treatment in adolescents with pulmonary arterial hypertension
CTR20222443Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Mar 2023; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20222443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222443.